Opening soon. Stay in the loop

goodmorrowJoin the opening list

MOTS-c, explained.

Mitochondrial open reading frame of the 12S rRNA-c. Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

Pharmacy catalog form

The routine

No dependable human wellness schedule is established by this research.

The evidence

Animal treatment research · human observations

Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.

Legal status
Backed by FDA advisers, awaiting final rule

FDA advisers voted 7 to 5 on July 23, 2026 to allow compounding, after reviewing it for obesity and osteoporosis. Not compoundable until the final rule.

At Goodmorrow
Waitlist open

What it is

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first described in 2015. In mice it improved insulin sensitivity and protected against weight gain on a high-fat diet.

What the evidence shows

Human evidence is early. There are small studies measuring natural MOTS-c levels in people, and very little on giving it as a treatment. The FDA reviewed it for obesity and osteoporosis.

How Goodmorrow handles it

If it becomes lawful, MOTS-c is a candidate for our GLP-1 Plus program. It won't replace medication with years of trial data behind it.

Stacks that include it

Follow updates about MOTS-c

Join the update list. This does not reserve a treatment or mean that future availability is assured.

What are you interested in?

We'll only use this to contact you about appointments, by phone, text or email. No health details needed here. See our privacy policy.

Questions people ask

Does MOTS-c cause weight loss?

It did in mice. Nobody has shown it in a proper human trial. For weight loss that's been proven in people, GLP-1 medication is the standard.

Sources

  1. FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
  2. Secondary sourceFDA Panel Votes to Loosen Restrictions for Four Peptides PharmExec, July 2026
  3. Research publicationThe Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance Cell Metabolism, 2015

Good days ahead.

Join the opening list for appointment updates.

Join the opening list